Division of Clinical and Population Sciences and Education, University of Dundee, Dundee, Scotland, United Kingdom.
J Clin Endocrinol Metab. 2011 Jan;96(1):E1-8. doi: 10.1210/jc.2010-0854. Epub 2010 Oct 6.
For patients with subclinical hyperthyroidism (SH), the objective of the study was to define the rates of progression to frank hyperthyroidism and normal thyroid function.
Record-linkage technology was used retrospectively to identify patients with SH in the general population of Tayside, Scotland, from January 1, 1993, to December 31, 2009.
All Tayside residents with at least two measurements of TSH below the reference range for at least 4 months from baseline and normal free T(4)/total T(4) and total T(3) concentrations at baseline were included as potential cases. Using a unique patient identifier, data linkage enabled a cohort of SH cases to be identified from prescription, admission, and radioactive iodine treatment records. Cases younger than 18 yr of age were also excluded from the study.
The status of patients was investigated at 2, 5, and 7 yr after diagnosis.
We identified 2024 cases with SH, a prevalence of 0.63% and an incidence of 29 per 100,000 in 2008. Most SH cases without thyroid treatment remained as SH at 2 (81.8%), 5 (67.5%), and 7 yr (63.0%) after diagnosis. Few patients (0.5-0.7%) developed hyperthyroidism at 2, 5, and 7 yr. The percentage of SH cases reverting to normal increased with time: 17.2% (2 yr), 31.5% (5 yr), and 35.6% (7 yr), and this was more common in SH patients with baseline TSH between 0.1 and 0.4 mU/liter.
Very few SH patients develop frank hyperthyroidism, whereas a much larger proportion revert to normal, and many remain with SH.
对于亚临床甲状腺功能亢进症(SH)患者,本研究旨在明确进展为显性甲状腺功能亢进症和甲状腺功能正常的发生率。
使用记录链接技术,从 1993 年 1 月 1 日至 2009 年 12 月 31 日,在苏格兰泰赛德的普通人群中回顾性地确定 SH 患者。
所有基线 TSH 至少两次低于参考范围至少 4 个月,且基线时游离 T4/总 T4 和总 T3 浓度正常的泰赛德居民均被纳入潜在病例。通过使用唯一的患者标识符,数据链接可识别出从处方、入院和放射性碘治疗记录中确定的 SH 病例队列。年龄小于 18 岁的病例也被排除在研究之外。
在诊断后 2、5 和 7 年时,对患者的状况进行了调查。
我们确定了 2024 例 SH 患者,2008 年的患病率为 0.63%,发病率为 29/10 万。大多数未经甲状腺治疗的 SH 病例在诊断后 2(81.8%)、5(67.5%)和 7 年(63.0%)时仍为 SH。少数患者(0.5-0.7%)在 2、5 和 7 年内发生了甲状腺功能亢进症。SH 病例恢复正常的比例随着时间的推移而增加:2 年时为 17.2%,5 年时为 31.5%,7 年时为 35.6%,且这种情况在基线 TSH 为 0.1 至 0.4 mU/l 之间的 SH 患者中更为常见。
极少数 SH 患者会发展为显性甲状腺功能亢进症,而更多的患者会恢复正常,且许多患者仍为 SH。